➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ruzasvir

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Ruzasvir?

Ruzasvir is an investigational drug.

There have been 8 clinical trials for Ruzasvir. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].

There are two US patents protecting this investigational drug and thirty-three international patents.

Recent Clinical Trials for Ruzasvir
Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)Merck Sharp & Dohme Corp.Phase 2
Efficacy and Safety of MK-3682 With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)Merck Sharp & Dohme Corp.Phase 2
Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)Merck Sharp & Dohme Corp.Phase 1

See all Ruzasvir clinical trials

Clinical Trial Summary for Ruzasvir

Top disease conditions for Ruzasvir
Top clinical trial sponsors for Ruzasvir

See all Ruzasvir clinical trials

US Patents for Ruzasvir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ruzasvir   Get Started Free Process for preparing substituted tetracyclic heterocycle compounds Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
Ruzasvir   Get Started Free Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ruzasvir

Drugname Country Document Number Estimated Expiration Related US Patent
Ruzasvir World Intellectual Property Organization (WIPO) WO2016196932 2035-06-04   Get Started Free
Ruzasvir Argentina AR094496 2033-01-16   Get Started Free
Ruzasvir Australia AU2013374112 2033-01-16   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.